Market Overview

Eli Lilly Reports Phase 3 Results of Solanezumab; Decline in Expedition1 Study Not Significant

Share:
Related LLY
Technical Alert: Eli Lilly Unchanged After Wild Ride Following Q2 Report
Earnings Scheduled For July 26, 2016
Leadership transition at Lilly, CEO Lechleiter to retire at year end (Seeking Alpha)

Eli Lilly and Company (NYSE: LLY) today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering committee for the ADCS.

Posted-In: News FDA

 

Related Articles (LLY)

View Comments and Join the Discussion!